Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989913 | 0.84 | ROCK2 (0.71) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL22165515 | 0.83 | ROCK2 (0.56) | ROCK2RPS6KB1 | |
| SCHEMBL1987650 | 0.80 | ROCK2 (0.81) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL24324813 | 0.80 | NPC1 (0.67) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL1987295 | 0.80 | NPC1 (0.60) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL22158357 | 0.74 | MAPT (0.57) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL22158344 | 0.74 | MAPT (0.57) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL22158313 | 0.74 | IMPDH2 (0.62) | NPC1L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL1988468 | 0.73 | ROCK2 (0.61) | NPC1L3MBTL1ROCK2AKT1RAB9A | |
| SCHEMBL1990148 | 0.73 | ROCK2 (0.70) | NPC1L3MBTL1ROCK2AKT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | NR2E3, GFRA2, ALDH1A2 | NPC1 4093/4885L3MBTL1 1828/4885ROCK2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.